Key Highlights
- Second-quarter revenue reached £8.41 billion, surpassing analyst projections of £8.24 billion
- Adjusted earnings per share of 50.5 pence exceeded the 47.1 pence estimate
- Specialty Medicines segment increased 14%, Vaccines climbed 8%; General Medicines declined 9%
- Company unveiled a £1.9 billion ($2.52 billion) efficiency program spanning three years
- Management maintained 2026 annual outlook, projecting turnover expansion toward the upper end of 3%–5% range
Shares of GSK advanced 4.2% on Tuesday following the British pharmaceutical company’s release of second-quarter financial results that exceeded Wall Street projections and the announcement of a significant efficiency initiative.
Second-quarter revenue totaled £8.41 billion, surpassing the analyst consensus estimate of £8.24 billion. Adjusted operating profit registered £2.80 billion compared to the £2.68 billion projection.
Core pre-tax profit reached £2.68 billion, exceeding the £2.52 billion expectation. Adjusted earnings per share of 50.5 pence outperformed the analyst consensus of 47.1 pence.
The pharmaceutical company announced a second-quarter dividend payment of 17 pence per share, matching market forecasts.
The Specialty Medicines division delivered exceptional results, with revenue advancing 14% to £3.8 billion. The Oncology segment expanded 17% while HIV treatments increased 10%.
Vaccines division revenue totaled £2.3 billion, representing an 8% increase. Shingrix generated £0.9 billion in sales, reflecting a 3% gain, while Meningitis vaccine sales more than doubled to £0.2 billion.
However, not all segments showed positive momentum. The General Medicines division contracted 9% to £2.3 billion. Trelegy revenue decreased 7% to £0.8 billion.
$2.5 Billion Efficiency Initiative
Concurrent with the quarterly results, GSK introduced a £1.9 billion ($2.52 billion) efficiency program spanning three years. The initiative aims to redirect resources toward financing advanced-stage pharmaceutical development.
Chief Executive Officer Luke Miels stated the initiative will “simplify the organisation and reallocate capital and resources” to bolster the late-stage development portfolio.
The cost reductions will partially finance what Miels characterizes as an accelerated drug development strategy — a critical objective as the company confronts impending patent expirations on multiple products.
Research Investment and UK Expansion
The pharmaceutical giant also revealed a £400 million commitment to UK operations, featuring a new research and development facility. This disclosure reinforces a comprehensive effort under Miels’ leadership to strengthen the company’s drug portfolio.
GSK has pursued an aggressive acquisition strategy. Last June, the company finalized what was characterized as its largest acquisition to date — the purchase of Nuvalent — as it expands its cancer treatment business.
Management has established an objective of achieving more than £40 billion in yearly revenue by 2031. Upcoming patent expirations over the next several years represent a significant challenge to achieving this target.
GSK maintained its 2026 full-year forecast, now indicating growth toward the upper portion of its 3%–5% revenue expansion guidance.
The stock traded 4.2% higher at 1120 GMT on Tuesday.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
